Comparison of Two Intraocular Gas Injection Techniques in Macula Hole Surgery

NCT ID: NCT04527848

Last Updated: 2020-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-10

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To undertake a prospective randomized clinical trial of vitrectomy and gas tamponade to treat macular hole, utilizing a small amount of undiluted C3F8 (perfluoropropane) versus a large amount of diluted C3F8 versus a small amount of undiluted SF6 (sulfur hexafluoride) versus a large amount of diluted SF6.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Holes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

macular holes Injections, Intra-Ocular gases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors
The individuals were randomized in a 1: 1: 1: 1 ratio. Block sizes of 4 individuals stratified according to gas type were used (SF6 or C3F8). In each block, two individuals were allocated to each group (0.9-1.0 mL of 100% gas or 15-20 mL of 20% gas).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

small amount of undiluted C3F8

Group Type EXPERIMENTAL

small amount of undiluted C3F8

Intervention Type DRUG

vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection

large amount of diluted C3f8

Group Type ACTIVE_COMPARATOR

small amount of undiluted C3F8

Intervention Type DRUG

vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection

small amount of undiluted SF6

Group Type ACTIVE_COMPARATOR

small amount of undiluted C3F8

Intervention Type DRUG

vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection

large amount of diluted SF6

Group Type ACTIVE_COMPARATOR

small amount of undiluted C3F8

Intervention Type DRUG

vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

small amount of undiluted C3F8

vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pseudophakia
* without previous vitreoretinal surgery
* diagnosed with a full-thickness macula hole on the optical coherence tomography exam.
* duration of symptoms less than 6 months
* inform consent

Exclusion Criteria

* ocular trauma
* allergy to any of the products used in the study,
* need to travel by plane in the first 60 postoperative days
* myopia over 6 diopters or axial diameter over 26 mm
* retinal dystrophies
* retinal detachment
* abnormal eye shape
* glaucoma
* diabetic retinopathy or other eye comorbidities.
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidade Federal de Pernambuco

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rodrigo Pessoa Cavalcanti Lira

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rodrigo PC Lira, PhD

Role: PRINCIPAL_INVESTIGATOR

UFPE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UFPE Ophthalmology

Recife, Pernambuco, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12347319.9.0000.8807

Identifier Type: -

Identifier Source: org_study_id